Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1719053

registered interest
date	17/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Methylphenidate
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she has had recent discussions with Janssen on the adequacy of supply of the ADHD medication Concerta XL.
tabling member constituency	Hornsey and Wood Green
tabling member printed	Catherine West
uin	26903
answer	answer is ministerial correction date of answer 23/05/2024 answer text <p>The Department has been working hard with industry to help resolve supply issues with some attention deficit hyperactivity disorder (ADHD) medicines, including Concerta XL tablets, which are affecting the United Kingdom and other countries around the world. This has involved asking that suppliers expedite deliveries to boost supplies of these important medicines, and addressing regulatory issues to ensure continuity of supply. As a result of our ongoing activity and intensive work, some issues have been resolved. We expect the disruptions to the supply of Concerta XL tablets to be resolved in May 2024.</p><p>The Department held a roundtable with all suppliers of methylphenidate prolonged-release tablet suppliers, including Janssen, in April 2024, to discuss the challenges they are facing, what they are doing, and what needs to be done to address these issues.</p><p>We have worked closely with specialist clinicians during this time to develop management advice for the National Health Service. The guidance includes advice for ADHD service providers and specialists to offer rapid response to primary care teams seeking urgent advice for the management of patients. This includes those known to be at a higher risk of adverse impact because of these shortages.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 26904 question first answered 23/05/2024 15:25:17 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4523 label Biography information for Catherine West

1719054

registered interest
date	17/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Methylphenidate
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure patients have access to Concerta XL.
tabling member constituency	Hornsey and Wood Green
tabling member printed	Catherine West
uin	26904
answer	answer is ministerial correction date of answer 23/05/2024 answer text <p>The Department has been working hard with industry to help resolve supply issues with some attention deficit hyperactivity disorder (ADHD) medicines, including Concerta XL tablets, which are affecting the United Kingdom and other countries around the world. This has involved asking that suppliers expedite deliveries to boost supplies of these important medicines, and addressing regulatory issues to ensure continuity of supply. As a result of our ongoing activity and intensive work, some issues have been resolved. We expect the disruptions to the supply of Concerta XL tablets to be resolved in May 2024.</p><p>The Department held a roundtable with all suppliers of methylphenidate prolonged-release tablet suppliers, including Janssen, in April 2024, to discuss the challenges they are facing, what they are doing, and what needs to be done to address these issues.</p><p>We have worked closely with specialist clinicians during this time to develop management advice for the National Health Service. The guidance includes advice for ADHD service providers and specialists to offer rapid response to primary care teams seeking urgent advice for the management of patients. This includes those known to be at a higher risk of adverse impact because of these shortages.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 26903 question first answered 23/05/2024 15:25:17 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4523 label Biography information for Catherine West

1716954

registered interest
date	09/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Infectious Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential implications for her policies of the report by Mahon, M.B. et al. entitled A meta-analysis on global change drivers and the risk of infectious disease, published in Nature on 8 May 2024.
tabling member constituency	Hornsey and Wood Green
tabling member printed	Catherine West
uin	25520
answer	answer is ministerial correction date of answer 15/05/2024 answer text <p>In December 2023 the UK Health Security Agency (UKHSA) published the Health Effects of Climate Change report, which is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/climate-change-health-effects-in-the-uk" target="_blank">https://www.gov.uk/government/publications/climate-change-health-effects-in-the-uk</a></p><p>This report details the potential risks and impacts of climate change on human health. The UKHSA will continue to work closely with other departments and agencies, to assess emerging evidence on drivers of infectious diseases, to inform future health policies.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 15/05/2024 10:04:41 answering member 4492 label Biography information for Maria Caulfield
tabling member	4523 label Biography information for Catherine West